Pyridopyrazine Derivatives for Dual Ras-Raf-Mek-Erk and Pi3k-Akt Pathway Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diseases related to the ras-Raf-Mek-Erk and PI3K-Akt signaling pathways, such as cancer and inflammatory diseases, lack specific and effective inhibitors that can modulate both pathways simultaneously, leading to unsatisfactory treatment outcomes.
Innovation Solution
Development of pyridopyrazine derivatives with specific substitutions that can inhibit or modulate the activity of key enzymes in the ras-Raf-Mek-Erk and PI3K-Akt signaling pathways, including compounds like 1-Allyl-3-(3-phenyl-pyrido[2,3-b]pyrazin-6-yl)-thiourea, which target serine/threonine and lipid kinases, offering a dual modulation approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies target only single signaling pathways (ras-Raf-Mek-Erk or PI3K-Akt separately), then pathway-specific inhibition is achieved, but treatment effectiveness is insufficient
Solution Approach 1:
The pyridopyrazine derivative compounds are designed to simultaneously inhibit multiple kinases across both ras-Raf-Mek-Erk and PI3K-Akt pathways, enabling a single agent to perform multiple therapeutic functions that previously required separate drugs
Solution Approach 2:
The invention merges the inhibition of serine/threonine kinases (Raf, Mek, Erk) and lipid kinases (PI3K) into a single compound class, combining what were previously separate therapeutic targets into one unified treatment approach
2Reliability
If specific kinase inhibitors are developed for each pathway component, then pathway selectivity is improved, but device/compound complexity increases
Solution Approach 1:
The patent optimizes specific molecular parameters of the pyridopyrazine core structure, including substituent types and positions, to achieve broad kinase inhibition while maintaining manageable structural complexity and drug-like properties
Data Source
AI summary
The invention relates to novel pyridopyrazine compounds which are suited for the treatment or prevention of physiological and/or pathophysiological conditions in mammals, especially humans, transmitted and/or modulated by signal transduction paths and/or enzymes.